echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Cell paper details! Reverse! Past exposure to seasonal coronavirus-producing antibodies that cause the common cold does not prevent SARS-CoV-2 infection

    Cell paper details! Reverse! Past exposure to seasonal coronavirus-producing antibodies that cause the common cold does not prevent SARS-CoV-2 infection

    • Last Update: 2021-02-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    in a new study, researchers from the University of Pennsylvania and Children's --- Hospital of Philadelphia found that past exposure to the seasonal coronavirus (CoV) that causes the common cold does not produce antibodies to prevent the new coronavirus SARS-CoV-2.
    results were published online February 9, 2021 in the journal Cell under the title "Lyst human coronavirus anti-boosted upon SARS-CoV-2 infected but not associated with protection".
    author of the paper is Dr. Scott Hensley, associate professor of microbiology at the Perelman School of Medicine at the University of Pennsylvania.
    from Cell, 2021, doi:10.1016/j.cell.2021.02.010.
    previous studies have shown that recent exposure to seasonal coronavirus may prevent SARS-CoV-2, the coronavirus that causes COVID-19.
    , however, the new study shows that even with such protection, it does not come from antibodies.
    Hensley said, "We found that before the COVID-19 pandemic, many people had antibodies that could bind to SARS-CoV-2, but they didn't prevent infection."
    Although antibodies previously produced by coronavirus infection do not prevent SARS-CoV-2 infection, earlier memory B and T cells may provide some degree of protection, or at least reduce the severity of coVID-19 disease.
    further research is needed to test this hypothesis.
    ", the researchers examined blood samples from hundreds of people before the COVID-19 pandemic.
    they found that more than 20 percent of these pre-COVID-19 pre-epidemic samples carried "cross-reactive" anti-CoV antibodies that bind not only to common cold-causing CoV, but also to key POINTS of SARS-CoV-2.
    , however, these cross-reactive antibodies were not able to neutrally neutrally infect SARS-CoV-2 and were independent of better clinical outcomes in people who were later infected with COVID-19.
    the researchers also found that children and adults tended to have similar levels of cross-reactive anti-CoV antibodies on average -- suggesting that these antibodies were not a factor in protecting most children from severe COVID-19.
    more than a year of global transmission, the COVID-19 pandemic has infected more than 100 million people, more than 2 million of whom have died.
    Although some risk factors, such as age, are clear enough, scientists still don't fully understand why some people develop COVID-19, while others have mild illnesses or even no symptoms.
    antibodies have been considered a possible explanation.
    common seasonal coronavirus that causes colds has long been circulating in the population.
    obvious assumption is that some of the antibodies caused by these common infections cross-react with the new coronavirus SARS-CoV-2, providing some degree of protection against at least severe COVID-19 disease.
    a group of analyses conducted by Hensley and his colleagues, they examined blood samples collected from 263 children at Children's Hospital of Philadelphia and 168 adults kept in the Pennsylvania Medical Biocosm.
    samples were taken in 2017, more than two years before the SARS-CoV-2 pandemic began.
    the researchers found that most of the 431 samples contained antibodies that were targeted to bind to common seasonal CoV.
    About 20 percent of the samples contained anti-CoV antibodies that "cross-react" with SARS-CoV-2, which bind closely to the spots on the virus's prickly protein and/or nuclear crust protein---, the two coronavirus proteins, which are most easily exposed to the infected host's immune system.
    Hensley and his colleagues analyzed blood samples stored before the COVID-19 pandemic from 251 people who later tested positive for SARS-CoV-2 (infected group), as well as a control group of 251 people who tested negative for the new coronavirus that matched their age and other related characteristics (non-infected group).
    they again found that more than 20 percent of the pre-COVID-19 samples contained anti-CoV antibodies that could cross-react with SARS-CoV-2 protrusion proteins and/or nuclear crust proteins.
    , however, the proportion of samples with these cross-reactive antibodies was similar in both the infected and non-infected groups, suggesting that the antibodies did not prevent SARS-CoV-2 infection.
    In addition, in people who were later infected with SARS-CoV-2 (infected group), their levels of cross-reactive anti-CoV antibodies in pre-COVID-19 pre-epidemic blood samples were not associated with the severity of COVID-19 ( e.g. whether hospitalization or intensive care was required).
    in the third set of tests, the researchers analyzed blood samples from 27 hospitalized COVID-19 patients and found that levels of these cross-reactive anticovants increased strongly in the COVID-19 course.
    the researchers suggest a larger study to determine whether existing anti-CoV antibodies can prevent SARS-CoV-2 infection.
    they also recommend further studies of other types of immune responses, such as T-cell responses, to see if they provide a degree of protective cross-reaction after seasonal CoV infection.
    At the same time, they say, their results suggest that the common bits where some antibodies bind to seasonal coronavirus and SARS-CoV-2 are not usually vulnerable points that SARS-CoV-2 can be mealed.
    (Bioon.com) :1. Elizabeth M. Anderson et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell, 2021, doi:10.1016/j.cell.2021.02.010.2.Antibodies to common cold coronaviruses do not protect against SARS-CoV-2
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.